Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness

被引：1
|
作者：
Bradbury, P. A.
Tu, D.
Seymour, L.
Ng, R.
Zhu, L.
Isogai, P. K.
Mittmann, N.
Evans, W. K.
Shepherd, F. A.
Leighl, N. B.
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[4] Juravinski Canc Ctr, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.6531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6531
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A COMPARATIVE CLINICAL AND COST-EFFECTIVENESS EVALUATION OF GEFITINIB AND ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Lopes, Gilberto D. L., Jr.
    Segel, Joel
    Tan, Daniel
    Do, Young
    Mok, Tony
    Finkelstein, Eric
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1306 - S1307
  • [2] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [3] COST-EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER IN CHINA
    Chen, W.
    Sheng, F.
    Qiao, N.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A276 - A276
  • [4] Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer
    Zhu Yu-jia
    Xia Ying
    Ren Guan-jun
    Wang Meng-zhao
    Zeng Xuan
    Zhang Li
    [J]. CHINESE MEDICAL JOURNAL, 2010, 123 (22) : 3200 - 3205
  • [5] Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer
    Pavlakis, N
    Mitchell, PL
    Slynes, G
    Aristides, M
    Davey, P
    Rajan, N
    Arora, B
    Liepa, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 549S - 549S
  • [6] COST-EFFECTIVENESS ANALYSIS (CEA) BETWEEN ERLOTINIB AND GEFITINIB FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN THAILAND
    Prasongsook, Naiyarat
    Jaruhathai, Sureerat
    Maoleekulpairoj, Savitree
    Sooksriwong, Chaoncin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1245 - S1246
  • [7] Predictors of erlotinib utilization and the impact of erlotinib use on overall survival in advanced, non-small cell lung cancer.
    Ersek, Jennifer L.
    Symanowski, James Thomas
    Kim, Edward S.
    Adams, Swann Arp
    Hebert, James R.
    Eberth, Jan Marie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
    Ahn, Myung-Ju
    Park, Byeong-Bae
    Ahn, Jin Seok
    Kim, Sang We
    Kim, Heung-Tae
    Lee, Jong Seog
    Kang, Jin Hyung
    Cho, Jae Yong
    Song, Hong Suk
    Park, Se Hoon
    Sohn, Chang Hak
    Shin, Sang Won
    Choi, Jin Hyuck
    Ki, Chang-Seok
    Park, Chan Keum
    Holmes, Alison J.
    Janne, Pasi A.
    Park, Keunchil
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (12) : 3860 - 3866
  • [9] Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach
    Fabienne Englmeier
    Annalen Bleckmann
    Wolfgang Brückl
    Frank Griesinger
    Annette Fleitz
    Klaus Nagels
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1495 - 1511
  • [10] Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach
    Englmeier, Fabienne
    Bleckmann, Annalen
    Brueckl, Wolfgang
    Griesinger, Frank
    Fleitz, Annette
    Nagels, Klaus
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (04) : 1495 - 1511
12345